|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology Pharmaceuticals Market in India 2012
Price: $795.00 (626.57) ($954.00 (751.89) Including VAT at 20%)
|
| Publication Date: Apr-2012
Pages: 71
Format: PDF
Publisher: Netscribes (India) Pvt. Ltd.
Sample Pages
Oncology pharmaceuticals market in India, a leading segment of the overall pharmaceuticals market is the fourth largest in volume and eighth largest in value in the global market. Since cancer is the second largest cause of death in the country, the Indian market is characterized by a huge demand for cancer drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the number of cancer cases, specially in lung cancer and breast cancer cases; changes in the cancer treatment scenario, development of alternative cancer therapies, increased cancer health insurance coverage and increasing amount of foreign direct investment (FDI) is helping the market to grow. The Indian Government, on its part is taking initiatives to work out public-private partnership projects (PPP) and reduce the essential drug prices. The market is expected to exhibit steady growth over the next few years.
The report begins with the market overview section which provides an insight into the global market, highlighting the market size and growth. It then moves onto the Indian market, with a focus on market size and growth. It also provides import and export figures of cancer drugs in India in terms of value. Regional break-up of the imports and exports have been included.
An analysis of the drivers explains the factors for growth of the industry including increasing cancer cases, changes in the treatment scenario, development of alternative cancer therapies, increasing FDI and increase in the number of cancer health insurances. The key challenges include increased competition, drug patent problems and drug portfolio management problems.
The government initiatives section highlights the PPP R&D projects started in the country. It also analyses the various initiatives undertaken to reduce prices of cancer drugs, the various cancer control programmes implemented and the changes in the custom duty structure.
A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals.
The competition section gives overview of pharmaceutical companies in the country operating in the oncology pharmaceutical industry. Thereafter, the report highlights the features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. Porters Five Forces Analysis has been incorporated for a brief but effective understanding of the market scenario. It also incorporates the recent developments in the Oncology Pharmaceutical industry.
The section on strategic recommendations elaborates on decisions that existing players as well as new entrants can find it useful. The foray into generic drugs is oncology segment can be beneficial for the players to a large extent.
Table of Contents |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology Pharmaceuticals Market in India 2011
Price: $795.00 (626.57) ($954.00 (751.89) Including VAT at 20%)
|
| Publication Date: Aug-2011
Pages: 41
Format: PDF
Publisher: Netscribes (India) Pvt. Ltd.
Oncology pharmaceuticals market in India, a leading segment of the overall pharmaceuticals market is the fourth largest in volume and eighth largest in value in the global market. Since cancer is the second largest cause of death in the country, the Indian market is characterized by a huge demand for cancer drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the number of cancer cases, specially in lung cancer and breast cancer cases; changes in the cancer treatment scenario, development of alternative cancer therapies, increased cancer health insurance coverage and increasing amount of foreign direct investment (FDI) is helping the market to grow. The Indian Government, on its part is taking initiatives to work out public-private partnership projects (PPP) and reduce the essential drug prices. The market is expected to exhibit steady growth over the next few years.
The report begins with the market overview section which provides an insight into the global market, highlighting the market size and growth. It then moves onto the Indian market, with a focus on market size and growth. It also provides import and export figures of cancer drugs in India in terms of value. Regional break-up of the imports and exports have been included.
An analysis of the drivers explains the factors for growth of the industry including increasing cancer cases, changes in the treatment scenario, development of alternative cancer therapies, increasing FDI and increase in the number of cancer health insurances. The key challenges include increased competition, drug patent problems and drug portfolio management problems.
The government initiatives section highlights the PPP R&D projects started in the country. It also analyses the various initiatives undertaken to reduce prices of cancer drugs, the various cancer control programmes implemented and the changes in the custom duty structure.
A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals.
The competition section provides an overview of the competitive landscape in the industry. It includes a brief profile of the major players in the market along with their financials. It also includes the latest developments in the industry.
Table of Contents |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Global Radiation Therapy Market Report: 2011 Edition
Price: $800.00 (630.51) ($960.00 (756.62) Including VAT at 20%)
|
| Publication Date: Oct-2011
Format: PDF Email
Pages: 47
Publisher: Koncept Analytics
Radiation Therapy refers to the medical use of ionizing radiation as a part of cancer treatment to control malignant cells by destroying their DNA. Various types of radiations are generally used for the treatment. Some of the major ones include: high energy photons, electron beams, proton beams and neutron beams. In the treatment, radiation can either come from a machine outside the body, called external beam radiation therapy or from radioactive material placed inside the body, which in this case is called internal radiation therapy or brachytherapy. Some of the major types of external radiation therapy treatments include: 3D-CRT, IMRT, IGRT, Tomotherapy, Stereotactic radiosurgery, SBRT and Proton Therapy.
Due to the increasing use of radiation therapy treatment, owing to its highly accurate and targeted nature, the radiation therapy market worldwide had witnessed double-digit growth in the past decade. The technological advancements taking place in the field have made the treatment more effective and precise, thereby improving its use. North America represents the largest RT market, followed by EMEA, both of which are generally characterized as replacement markets. Asia Pacific and Latin America offer potential for future growth in the new installations.
There are many opportunities which would benefit the market in future; some of them include the low penetration rates in the emerging countries, the ageing of the RT equipments in developed regions, and the proton therapy treatment. Also, the increasing number of cancer cases, growth in obese population, increasing consumption of alcohol and tobacco, and improving reimbursement trends are few important drivers affecting the industry.
The global radiation therapy market, including the hardware and software products is highly consolidated with the majority of the market being in the hands of a few companies. Among all, Varian is the market leader, followed by Elekta and Siemens.
This report analyzes the global radiation therapy market with focus on regional markets like North America, EMEA, Asia Pacific and Latin America. The report presents some of the major drivers, opportunities and challenges being faced by the industry. It also analyzes the competitive scenario of the global radiation therapy market, along with the competitive conditions being faced in North America, Europe and Asia Pacific. The profiles of the four major players, Varian, Elekta, Siemens, and Accuray are being included in the report.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables, and tests.
Table of Contents/List of Tables/List of Figures |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Global Lung Cancer Surgery Market (Devices & Treatment Outlook) – Trends & Challenges (2010 – 2015)
|
Price
|
| Publication Date: Jul-2011
Format: PDF
Pages: 228
Publisher: MarketsandMarkets
Table of Contents
Lung cancer is the most common type of cancer across the globe. According to WHO, lung cancer is expected to be more prominent in the underdeveloped world due to an increase in the use of tobacco products; tobacco is the primary cause of around 80% of all lung cancers. Global incidence of lung cancer was 1,608,055 in 2008 with the developing countries accounting for a major share (55%); 1,694,277 new cases were recorded in 2010 with 1,934,467, 2,213,561, and 2,530,820 as the predicted new cases for the years 2015, 2020, and 2025 respectively.
More... |
|
|
|
|
|
|
Breast Cancer Market Report: 2011 Edition
Price: $800.00 (630.51) ($960.00 (756.62) Including VAT at 20%)
|
| Publication Date: Jun-2011
Format: PDF Email
Pages: 39
Publisher: Koncept Analytics
Breast cancer is one of the most common types of cancer after lung cancer and the second leading cause of death in women. Globally, more than one million women are diagnosed with breast cancer annually. Breast cancer is mainly found in women compared to men. Though women of all ages are at risk of developing breast cancer, older woman have greater chances of developing it. The incidence rates of breast cancer vary noticeably; registering the highest rate in the US followed by Europe and the lowest rate in Africa and Asia.
Breast cancer usually affects women over the age of 40 and above. In the past few years, the cases of breast cancer have increased tremendously in western countries like the US and Europe. The breast cancer market is comprised of three segments: screening, diagnostic and treatment. The breast cancer market is driven by various factors like aging population in women, obesity, hormonal factors and family history amongst others.
The market for breast cancer drugs represents an area of potential opportunity in both developed and developing countries. Due to effectiveness and advancement in technology, a large number of companies are focusing to develop innovative breast cancer drugs. Further, the companies are forming alliances and agreements to develop effective treatment methods for breast cancer.
The stages of breast cancer are of critical importance and they alone determine the treatment method and the extent to which it can be cured. Mammography is believed to diagnose 85-90% of breast cancers in women over 50, and is capable of identifying a lesion one to four years before a lump can be felt. Biopsy is used for the diagnosis of breast cancer once a lesion is detected in screening. For treatment of breast cancer, the first method to be used is surgical, followed by drugs and radiation therapy or both.
This report provides an overview of breast cancer, its types and stages, and incidence rates. The markets for screening, diagnosis and treatment of breast cancer, including mammography, biopsy, chemotherapy, radiotherapy and drugs, have been analyzed. It also analyzes the drivers, issues and trends in the breast care market. The major players in the market are profiled along with their financials and key business strategies.
Table of Contents/List of Tables/List of Figures |
|
|
Epidemiology: Endometrial Cancer - Postmenopausal women are at the most risk for developing endometrial cancer; aging populations will drive an increase in cases
Price: $5,700.00 (4,492.42) ($6,840.00 (5,390.90) Including VAT at 20%)
|
| Publication Date: 11-Mar-2011
Please click here for more information or to purchase this report at our partner store
Overview of endometrial cancer defintion and a review of the epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets. |
|
|
Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development
Price: $1,900.00 (1,497.47) ($2,280.00 (1,796.97) Including VAT at 20%)
|
| Publication Date: 04-Mar-2011
Please click here for more information or to purchase this report at our partner store
Overview of targeted cancer therapies and biomarkers, with in-depth analysis of drug and companion diagnostic development, commercial potential, role of regulatory authorities in the seven major markets and key pipeline personalized cancer therapies. |
|
|
Epidemiology: Prostate Cancer - Incidence and prevalence reaches new heights due to testing, risk factors, and an aging population
Price: $5,700.00 (4,492.42) ($6,840.00 (5,390.90) Including VAT at 20%)
|
| Publication Date: 29-Mar-2011
Please click here for more information or to purchase this report at our partner store
Overview of prostate cancer definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets. |
|
|
Epidemiology: Renal cell cancer - The number of incident cases are expected to soar during the forecast period
Price: $3,800.00 (2,994.94) ($4,560.00 (3,593.93) Including VAT at 20%)
|
| Publication Date: 28-Mar-2011
Please click here for more information or to purchase this report at our partner store
Overview of renal cell cancer definition and a reivew of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epidemiology: Cervical Cancer
Price: $5,700.00 (4,492.42) ($6,840.00 (5,390.90) Including VAT at 20%)
|
| Publication Date: 15-Feb-2011
Please click here for more information or to purchase this report at our partner store
Overview of cervical cancer definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets. |
|
|
Epidemiology: Endometrial Cancer
Price: $5,700.00 (4,492.42) ($6,840.00 (5,390.90) Including VAT at 20%)
|
| Publication Date: 11-Mar-2011
Please click here for more information or to purchase this report at our partner store
Overview of endometrial cancer defintion and a review of the epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets. |
|
|
Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development
Price: $1,900.00 (1,497.47) ($2,280.00 (1,796.97) Including VAT at 20%)
|
| Publication Date: 04-Mar-2011
Please click here for more information or to purchase this report at our partner store
Overview of targeted cancer therapies and biomarkers, with in-depth analysis of drug and companion diagnostic development, commercial potential, role of regulatory authorities in the seven major markets and key pipeline personalized cancer therapies. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Cancer Market Outlook To 2015
Price: $3,835.00 (3,022.53) ($4,602.00 (3,627.03) Including VAT at 20%)
|
| Publication Date: 26-Aug-2010
Please click here for more information or to purchase this report at our partner store
The cancer market is becoming increasingly competitive. The key challenge in ensuring commercial success of new drugs is to ascertain their integration into current treatment regimens or by demonstrating superiority over existing regimens. |
|
|
Stakeholder Insight: Gastric Cancer
Price: $15,200.00 (11,979.77) ($18,240.00 (14,375.73) Including VAT at 20%)
|
| Publication Date: 15-Sep-2010
Please click here for more information or to purchase this report at our partner store
Explores key issues in the gastric cancer market, including diagnosis and treatment patterns, specific drug regimens used at each line of therapy, key prescribing influences and predicted performance of late-phase pipeline products. |
|
|
|
|
Stakeholder Opinions: Hepatocellular cancer
Price: $3,800.00 (2,994.94) ($4,560.00 (3,593.93) Including VAT at 20%)
|
| Publication Date: 01-Dec-2010
Please click here for more information or to purchase this report at our partner store
Stakeholder Opinions: Hepatocellular Cancer discusses issues in the treatment of hepatocellular cancer, highlighting potential target populations for drug developers, treatment limitations and unmet needs, and an overview of the current pipeline. |
|
|
Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Herceptin dominates the HER-2-positive market
Price: $15,200.00 (11,979.77) ($18,240.00 (14,375.73) Including VAT at 20%)
|
| Publication Date: 03-Nov-2010
Please click here for more information or to purchase this report at our partner store
Primary research-based analysis of the hormone receptor-positive breast cancer market. Includes epidemiology, patient segmentation, treatment trends, and future treatment scenarios. Separate coverage of triple-negative and HER-2-positive subsets. |
|
|
Epidemiology: Gastric Cancer
Price: $5,700.00 (4,492.42) ($6,840.00 (5,390.90) Including VAT at 20%)
|
| Publication Date: 13-Dec-2010
Please click here for more information or to purchase this report at our partner store
Overview of gastric cancer definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets. |
|
|
Epidemiology: Hepatocellular Cancer
Price: $5,700.00 (4,492.42) ($6,840.00 (5,390.90) Including VAT at 20%)
|
| Publication Date: 12-Dec-2010
Please click here for more information or to purchase this report at our partner store
Overview of hepatocellular cancer definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets. |
|
|
Epidemiology: Ovarian Cancer
Price: $5,700.00 (4,492.42) ($6,840.00 (5,390.90) Including VAT at 20%)
|
| Publication Date: 12-Dec-2010
Please click here for more information or to purchase this report at our partner store
Overview of ovarian cancer definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets. |
|
|
Epidemiology: Breast Cancer
Price: $5,700.00 (4,492.42) ($6,840.00 (5,390.90) Including VAT at 20%)
|
| Publication Date: 17-Dec-2010
Please click here for more information or to purchase this report at our partner store
Overview of breast cancer definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets. |
|
|
Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report
|
| Please click here for more information or to purchase this report at our partner store
Published: January 2011
Pages: 139
This market report from Select Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two areas are evolving and expanding driven by the greater emphasis on personalized medicine especially in the cancer/oncology space.
Cancer vaccines can be generated using a number of different approaches and this report describes these approaches vis-à-vis their advantages and disadvantages and associated technical characteristics. Indeed, the FDA-approval of a cancer vaccine for prostate cancer in 2010 was a key milestone in this space and a driver for R&D efforts forward. This report presents the pre-clinical pipeline, early-stage clinical trial pipeline, and the late-stage clinical pipeline for the cancer vaccines space. Also presented are the failed vaccine candidates with a discussion about these failures and how the industry can benefit via a deeper understanding of what components are required for effective immune system activation in vivo and effective vaccination—either preventative or therapeutic.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Global Radiation Therapy Market: 2010 Edition
Price: $800.00 (630.51) ($960.00 (756.62) Including VAT at 20%)
|
| Publication Date: 01-Aug-2010
Format: PDF
Pages: 43
Publisher: Koncept Analytics
The global radiation therapy market has witnessed a double digit growth rate during the last few years. The industry growth was driven by technological advancements which have made radiation therapy more effective, precise and above all commercially viable. Higher cancer incidence and favorable reimbursement policy in the developed countries like U.S., U.K. further helped the industry in achieving double digit growth rate. The U.S. is the largest radiation therapy market with fifty percent share of the global market. The market growth has been driven by high rate of cancer incidence in the country, rapid acceptance of new and advanced treatment methods and favorable reimbursement policy for cancer treatment through radiation therapy. Europe is the second largest market with about one-third of the global market. Over the last few years, primary growth markets have been the developed nations. However, it is expected that in the next few years the demand from these countries will witness a decline as they face economic woes like high fiscal deficit, slow recovery and high unemployment rate. The major growth drivers over the next few years will be the developing nations as there will be significant increase in demand for radiation therapy equipments and cancer drugs from these countries. The demand will increase as these economies are facing high incidence of cancer and lack proper cancer treatment infrastructure. Also, the governments in these economies have started taking initiatives like increasing number of cancer treatment centers. Private hospitals are also expected to make huge investments in creating better cancer treatment facilities. Thus, as demand from developed economies will decline, it will get offset by an increase in demand from developing nations. The report provides an in-depth analysis of the global radiation therapy market. The various drivers, opportunities and the challenges faced by the market are discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market. By combining SPSS Inc.s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Table of Contents/List of Tables/List of Figures |
|
|
Stakeholder Insight: Non-Hodgkin's Lymphomas Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)
Price: $15,200.00 (11,979.77) ($18,240.00 (14,375.73) Including VAT at 20%)
|
| Publication Date: 17-Dec-2009
Please click here for more information or to purchase this report at our partner store
Primary research-based analysis of the non-Hodgkin's lymphomas market, including epidemiology, patient segmentation, and treatment data. Separate coverage of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). |
|
|
|
|
Stakeholder Insight: Cancer Pain - Physician survey highlights inadequacies in education and treatment
Price: $15,200.00 (11,979.77) ($18,240.00 (14,375.73) Including VAT at 20%)
|
| Publication Date: 23-Dec-2009
Please click here for more information or to purchase this report at our partner store
Datamonitor surveyed 180 oncologists, anesthetists, palliative medicine specialists and pain care specialists in the seven major markets to gain insight into cancer pain prevalence, treatment trends and key prescribing influences. |
|
|
Stakeholder Opinions: Melanoma - Future treatment will be based on individual tumor gene expression signatures
Price: $3,800.00 (2,994.94) ($4,560.00 (3,593.93) Including VAT at 20%)
|
| Publication Date: 31-May-2010
Please click here for more information or to purchase this report at our partner store
Key issues in the melanoma market including forecast epidemiology data, current treatment patterns and controversies, unmet needs, insight into late-phase pipeline drugs and key stakeholder opinions. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Breast Cancer Market? An Analysis
Price: $800.00 (630.51) ($960.00 (756.62) Including VAT at 20%)
|
| Publication Date: 01-Jan-2010
Format: PDF Email
Pages: 39
Publisher: Koncept Analytics
Breast cancer is the second most common type of cancer after lung cancer worldwide and the fifth most common cause of cancer death. It is found more in women as compared to men. Worldwide more than one million new cases of breast cancer are found every year. New breast cancer cases are mostly found in North America. Breast cancer is usually found in women over the age of 40 years. Breast cancer cases have risen about 30% in the past 25 years in western countries like the US and Europe. Breast cancer market is comprised of two segments - diagnostic and therapy. The key drivers of breast cancer market are aging population, obesity and family history among others. The stages of breast cancer are of critical importance and decide the treatment method and the extent to which it can be cured. Mammography is believed to find 85% to 90% of breast cancers in women over 50, and can discover a lesion one to four years before a lump can be felt. In case of patients with dense breast tissue, breast implants or patients who are breastfeeding, mammography cannot produce clear images and therefore, in such cases, ultrasound or MRI is recommended. Biopsy is used for the diagnosis of breast cancer once a lesion is detected in screening. For treatment of breast cancer, surgery is used first and then drugs or radiation therapy or both are used. The major players of breast cancer market are strengthening their networks through international alliances, agreements, strategic acquisitions, exploring new markets and R&D initiatives that will help in more effective diagnosis and treatment of breast cancer. This report provides an overview of the breast cancer, its types and stages, and incidence rates. The markets for diagnosis and treatment of breast cancer have been analyzed. Markets for diagnosis and treatment like, mammography, biopsy, chemotherapy, radiotherapy and drugs have also been discussed. The report also analyzes the drivers, issues and trends in the breast care market. The major players in the market are profiled along with their key business strategies.
Table of Contents/List of Tables/List of Figures |
|
|
Apoptosis 2009: Opportunities in Cancer and Other Diseases
|
| Please click here for more information or to purchase this report at our partner store
Published: 01/02/2009
Pages: 310
Format: PDF
Publisher: Select Biosciences
Apoptosis is regarded as the major mode of cell death in cancer and is therefore an important target for antineoplastic drugs. This report reviews 370 apoptosis-modulating drug candidates (80% for cancer, 9% in Phase III or later) with 148 molecular targets under development by 233 companies. It also provides in-depth analysis and market forecasts |
|
|
Be alerted by email of new featured reports
Browse upcoming events or submit your own